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To determine clinical, laboratory features and outcomes of Multisystem Inflammatory Syn-
drome in children (MIS-C) and its comparison with historic Kawasaki Disease (KD) and Viral
Myocarditis (VM) cohorts.
Methods
All children (1 month– 18 years) who fulfilled the World Health Organization criteria of MIS-C
presenting to two tertiary care centers in Karachi from May 2020 till August 31st were
included. KD and VM admitted to one of the study centers in the last five years prior to this
pandemic, was compared to MIS-C.
Results
Thirty children with median age of 24 (interquartile range (IQR)1–192) months met the crite-
ria for MIS-C. Three phenotypes were identified, 12 patients (40%) with KD, ten (33%) VM
and eight (26%) had features of TSS. Echocardiography showed coronary involvement in
10 (33%), and moderate to severe Left Ventricular dysfunction in 10 (33%) patients. Ste-
roids and intravenous immunoglobulins (IVIG) were administered to 24 (80%) and 12 (41%)
patients respectively while 7 (23%) received both. Overall, 20% children expired. During the
last five years, 30 and 47 children were diagnosed with KD and VM, respectively. Their com-
parison with MIS-C group showed lymphopenia, thrombocytosis, and higher CRP as well as
more frequent atypical presentation in MIS-C KD group with less coronary involvement. The
MIS-C VM was more likely to present with fulminant myocarditis.
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Conclusions
Our MIS-C cohort is younger with higher mortality compared to previous reports. MIS-C is
distinct from historic cohorts of KD and VM in both in clinical features and outcomes.
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related disease (COVID-19)
has been reported to have lesser and a milder disease presentation in children [1, 2]. However,
in April,2020 there were reports from United States, Italy and other parts of the world describ-
ing a multi system inflammatory syndrome in children [3–5]. These reports described children
presenting with a spectrum of clinical features with similarities to Kawasaki disease (KD),
toxic shock syndrome (TSS) and viral myocarditis (VM). World Health Organization (WHO),
Royal College of Pediatrics and Child Health (RCPCH) of United Kingdom and the Center for
Disease Control (CDC) published criteria for diagnosed with MIS-C [6–8].
After the initial reports from USA and Europe, reports have also been published from Paki-
stan, India, and South Africa with almost similar spectrums of presentations of MIS-C [9–11].
The report of eight cases published from Lahore, Pakistan showed high incidence of coronary
involvement (62.5%) while cardiac dysfunction was not a prominent feature in these patients.
Karachi is the largest city of Pakistan and had the highest density of overall cases. As of 30th
November 2020, there have been 398,024 cases of COVID-19 in Pakistan, and children consti-
tute around 10% of total cases [12]. The Aga Khan University Hospital (AKUH) and National
Institute of Cardiovascular Disease (NICVD) are the two largest tertiary care pediatric centers
in Karachi, Pakistan and serve as major referral centers for any complex patient with cardiac
involvement or requiring pediatric intensive care unit (PICU) care. These institutions edu-
cated the primary care providers via live webinars and, social media about MIS-C and devel-
oped a common management algorithm for MIS-C patients (S1 Appendix).
In this study, we describe the clinical and laboratory features of children diagnosed with
MIS-C at these sites with 2 months follow up and furthermore provide a comparison with
5-year historic data of patients diagnoses with KD and VM at AKUH. This comparison pro-
vides insights into the similarities and differences of MIS-C with KD and VM.
Methods
Retrospective observational study was conducted at the two centers from 1st April through 31st
August after approval from ethical review committee. The waiver of consent was granted for
this study. (Reference # 2020-5715-14993). All children fulfilling the WHO’s MIS-C case defi-
nition, except for history of contact/exposure, were included. Children with a clear alternative
etiological classification were excluded. We retrospectively reviewed data of patients diagnosed
as KD and myocarditis at AKUH during the previous five years prior to the pandemic and
compared the clinical and laboratory features of these children with MIS-C related KD and
myocarditis. We also compared the laboratory parameters, disease spectrum of MIS-C and
outcome of patients with and without known history of contact.
Data collection and analysis
Data was extracted on a structured case report form from patients’ medical records. Data col-
lection included demographic information (age, gender), clinical data (symptoms on presenta-
tion, clinical examination findings, relevant laboratory test result and echocardiographic
PLOS ONE Multisystem inflammatory syndrome in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0253625 June 21, 2021 2 / 13
details, SARS-CoV-2 polymerase chain reaction (PCR) test result, SARS-CoV-2 antibody test),
management details (antibiotics, antivirals, immunoglobulin, steroids), need for PICU admis-
sion, their outcome and follow up. All patients were followed as per protocol (supplementary
material) with latest follow-up till 15th October 2020.
Based on their clinical presentation, patients were grouped into three main categories: a)
KD like illness including KD and atypical KD definition according to AHA (labelled as MIS-C
KD) [10]; and Non KD like illness which was subdivided into b) TSS (MIS-C TSS) and c) VM
(MIS-C VM) as described in Table 1. These three groups were then compared using ANOVA
(Analysis of Variance) for normally distributed variable, Kruskul Wallis test for non-normally
distributed variables and Chi-square test for categorical variables. The MIS-C KD group were
also compared to historic KD and MIS-C VM to Historic VM from last 5 years. Multiple com-
parison test was performed for those clinical or laboratory features whose overall significance
were found p< 0.05 using Tukey test for normally distributed, Kruskul Wallis post hoc test
for non-normally distributed variables. P-values are adjusted for multiple comparison using
Bonferroni Method. Multinomial regression was also performed to predict the phenotype of
disease form clinical and laboratory representation.
Data was entered and analyzed using STATA version 15.0. Results are presented as
mean ± Standard deviation (SD) or median with interquartile range (IQR) and frequency with
percentage. Appropriate statistical tests (Pearson chi-squared for categorical variable, two sam-
ple t-test for continuous normally distributed data and Wilcoxon rank sum test for non-nor-
mal data) were applied. A p value of<0.05 was taken as significant.
Results
Study population and characteristics
A total of 30 patients (77%) males) were included. Median age of the study population was 24
(IQR 9.5–60) months and 13 (44%) were under the age of 2 years (Table 2). The most consis-
tent presenting symptom was fever (100%), with a median duration of 4 (IQR 3–5) days fol-
lowed by Gastrointestinal symptoms (n = 21, 70%), rash (n = 16, 53%), hypotension (n = 14,
47%) and central nervous system symptoms like irritability, convulsions, and delirium (n = 11
(37%). Twelve patients (40%) had features of KD (MIS-C KD), 10 (33%) had myocardial dys-
function (MIS-C VM), and 8 (26%) had features of TSS (MIS-C TSS). The description of dif-
ferent clinical, laboratory and outcome features of three phenotype of MIS-C is presented in
Table 2.
Eighty six percent of patients (26/30) were tested using SARS-CoV-2 PCR and 14/26
(53.8%) were positive. COVID-19 serology was done in remaining 7/12 (23%) and all were
reactive. Serology was not performed in those with positive PCR due to cost issues. Four
patients in our cohort unfortunately did not get either PCR or antibody but were included
based on clinical suspicion and history of contact (Fig 1). Positive contact history for COVID-
19 was present in 21/30 (70%) patients. There was no difference between symptoms at presen-
tation, demographics, laboratory parameters and outcomes between patient with or without a
history of contact (Table 1 in S2 Appendix).
Clinical phenotypes
There was total 12 patients with MIS-C KD like illness during the pandemic. Distinct labora-
tory features are described in Table 2. Nine (75%) patients were diagnosed as atypical KD and
3 (25%) were diagnosed as KD. Coronary involvement was seen in 7/12 (58.3%) patients. Four
(57%) had perivascular brightness, two had coronary dilation and one had severe coronary
aneurysm formation. IVIG was administered in 10/12 (83%) patients and all 12 patients
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survived. Complete coronary resolution was seen in 6/7 (85%) patients on a median follow up
of 1 month. Ten patients (33%) presented with MIS-C VM and 8(26%) with MIS-C TSS
(Table 2). On comparing the 3 phenotypes, only significant difference after Bonferroni correc-
tion, was use of IVIG in MISC-KD group. The p-value of 0.045 in Trop-I levels in MISC-VM




MIS-C was defined as any patient fulfilling the criteria defined by WHOα
except for requirement for SARS-CoV-2 exposure contact history as that
was hard to ascertain without the presence of widespread testing in the
country.
Kawasaki Disease (KD) Like illness Was diagnosed using the validated diagnostic criteria of the American
Heart Association [13]. The group was subdivided in to KD and atypical
KD. KD is diagnosed in the presence of fever for at least 5 d (the day of
fever onset is taken to be the first day of fever) together with at least 4 of
the 5 following principal clinical features.
1.Erythema and cracking of lips, strawberry tongue, and/or erythema of
oral and pharyngeal mucosa.
2.Bilateral bulbar conjunctival injection without exudate.
3.Rash: maculopapular, diffuse erythroderma, or erythema multiforme-
like.
4.Erythema and edema of the hands and feet in acute phase and/or
periungual desquamation in sub-acute phase
5.Cervical lymphadenopathy (�1.5 cm diameter), usually unilateral
Atypical KD: Presence fever > 5days and 2–3 KD criteria
With positive echocardiogram OR 3 or more Laboratory findings:
1. Anemia for age
2. Increased Platelets> 7 days of fever.
3. Albumin < 3.0 g/dl
4. Elevated ASTβ ALT1
5. WBCπ> 15000
6. Pyuria.
Coronary artery involvement1 Coronary involvement was categorized as only echo brightness without
any ectasia or coronary dilation, and/or coronary aneurysm. Coronary
dilation was defined as coronary artery diameter z-score of > + 2 to +3
while coronary artery diameter with a z score > +3 was labelled as severe
ectasia or aneurysm. Echo brightness was described as appearance of
bright broad echoes surrounding the coronary lumen extending for at
least 1 cm along the artery, as compared to thin parallel echoes
representing normal coronary artery walls distinct from the surrounding
[14].
The Non KD like illness A. Viral Myocarditis (VM)
�Age related tachycardia, tachypnea, hypotension, elevated levels of pro–
brain natriuretic peptide (proBNP) troponin (all during the first 24 hours
of admission) and depressed LV£ function
� Depressed LV function was defined as LV ejection fraction (LVEF)
of < 50% and severe depressed as LVEF <30%.
B. Toxic Shock Syndrome (TSS) like illness was defined was described as
with signs of distributive shock, multi-organ injury and systemic
inflammation. There will be age related tachypnea tachycardia
hypotension, not responding to fluid boluses and requiring two inotropic





πWBC: White blood cell
αWHO: World Health Organization.
https://doi.org/10.1371/journal.pone.0253625.t001
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Table 2. Comparison of clinical and laboratory features of children presenting with multisystem inflammatory syndrome (MIS-C) (n = 30).
Characteristics MIS-C KDa MIS-C VMb MIS-C TSSc Total
N = 12 N = 10 N = 8 N = 30 P-value
Demographic Characteristics
Age in Month, Median (IQR) 27 (9–60) 18(9.5–42) 30 (9.9–174) 24(9.5–60) 1.000
Gender, n (%) 1.000
Male 11 (92%) 6 (60%) 6 (75%) 23 (77%)
Female 1 (8%) 4 (40%) 2 (25%) 7 (23%)
Symptoms on Admission
Fever 12 (100%) 10 (100%) 8 (100%) 30 (100%) —
Length of Fever in Days, Median (IQRd) 5 (4–7) 4 (3–5) 5 (3–5) 4 (3–5) 1.000
Vomiting/Diarrhea 7 (58%) 6(60%) 8 (100%) 21 (70%) 1.000
Delirium, irritability, or convulsions 4 (33%) 4 (40%) 3 (38%) 11 (37%) 1.000
COVID-19 PCR eTest Done 12(100%) 6(60%) 8(100%) 26(86.67%) 1.000
Positive 4 (33%) 5 (83%) 5 (63%) 14 (54%)
Negative 8 (67%) 1 (17%) 3 (38%) 12 (46%)
COVID-19 antibody Test Done 5 (41%) 0 (0%) 2 (25%) 7(23%) 0.09
Positive 5 (100%) 0(0%) 2 (100%) 7 (100%)
Negative 0 (0%) 0(0%) 0(0%) 0 (0%)
Leucocyte, Median (IQR) (×109/L) 11(9–14) 9.05 (6.7–12.2) 15.5 (10–19) 11 (9–16) 1.000
Neutrophils, Median (IQR) (%) 75 (68–81) 73 (64–75) 86 (66–87) 75 (65–85) 1.000
Lymphocytes, Median (IQR) (%) 17 (12–22) 20 (15–30) 11 (10–26) 18 (11–24) 1.000
Platelets Count, Median (IQR) (×109/L) 304 (245–389) 225 (129–335) 152 (96–224) 230 (140–330) 0.300
CRPf, Median (IQR) (mg/L) 67.91 (25–167) 26(1.10–61) 19.50 (6.7–93.7) 31.00 (3.05–84.85) 1.000
D-Dimer Median (IQR) (ng/ml) 30 (2.3–99) 15 (0.20–30.00) 12.00 (1.40–18.00) 3.6(2.1–9.6) 1.000
Ferritin, Median (IQR) (ug/L) 567 (151–1491) 224(99–656) 673(316–1480) 587 (276–1111) 1.000
LDHh, Median (IQR) (IU/L) 575 (333–1933) 1650 (460–980) 408(208–830) 617 (372–1696) 1.000
LVEFi on Admission, Median (IQR) (%) 57 (46–61) 30 (25–45) 40(39–57) 46 (30–61) 1.000
Coronary Involvement n (%) 7 (58%) 0 (0%) 3 (38%) 10 (33%) 1.000
Dilation 1 (14%) 0 (0%) 1 (33%) 2 (20%)
Aneurysm 2 (29%) 0 (0%) 0 (0%) 2 (20%)
Echo bright 4 (57%) 0 (0%) 2 (67%) 6 (60%)
Treatment
PICU j Admission 10 (83%) 9 (90%) 8 (100%) 27(88%) 1.000
Mechanical Ventilation 0 (0%) 9(90%) 4(50%) 12(40%) 0.675
Inotrope Support 4(33%) 10(100%) 8(100%) 22(73%) 1.000
Steroids 7 (58%) 9 (90%) 8 (100%) 24 (80%) 0.964
IVIGk 10 (83%) 0 (0%) 2 (25%) 12 (41%) <0.001
Both Steroids and IVIG 5 (42%) 0 (0%) 2 (25%) 7 (23%) 1.000
Anticoagulation 12 (100%) 6 (60%) 5 (63%) 23 (77%) 0.705
Follow-Up 0.1.35
Yes 12 (100%) 3 (43%) 6 (86%) 21 (81%)
No 0 (0%) 2 (57%) 1 (14%) 5 (19%)
Outcome 0.180
Survived 12 (100%) 5 (50%) 7 (88%) 24 (80%)
(Continued)
PLOS ONE Multisystem inflammatory syndrome in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0253625 June 21, 2021 5 / 13
and< 0.001 in presence of Rash in MISC-KD group was part of operational definition so were
not considered significant. Due to small sample size, we could not construct a multi-variate
model to predict phenotype from the clinical and laboratory data (Table 4 in S2 Appendix).
Management and outcome data
Overall, 26/30 (80%) patients were admitted to the PICU, 22(73%) required inotropic support
and 20(40%) mechanical ventilation. Intravenous steroids were given to 24 (80%) patients and
intravenous immunoglobulins (IVIG) was administered to 12 (41%) patients while 7 (23%)
received both IVIG and steroids. Anticoagulation was prescribed to 23 patients (77%). Overall
mortality was 20% (6/30). These 6 patients are described individually in Table 3 in S2
Appendix.
There was 100% survival and follow up in the MIS-C KD group. IVIG was administered in
10 (83%) patients. They were kept on low dose Aspirin and followed-up with a transthoracic
echocardiogram, with 85% (6/7) resolution of coronary involvement.
Table 2. (Continued)
Characteristics MIS-C KDa MIS-C VMb MIS-C TSSc Total
N = 12 N = 10 N = 8 N = 30 P-value
Demographic Characteristics
Expired 0 (0%) 5 (50%) 1 (13%) 6 (20%)
KD = Kawasaki disease
bVM = viral myocarditis
cTSS = Toxic shock syndrome
dIQR = Interquartile range, ePCR = Polymerase chain reaction
fCRP = c-reactive protein
hLDH = lactate dehydrogenase
iLVEF = left ventricular ejection fraction
jPICU = pediatric intensive care unit
k IVIG = intravenous immunoglobulin showed, α = statistical difference was found in group MIS-C KD after performing pair comparison Kruskul Wallis test
https://doi.org/10.1371/journal.pone.0253625.t002
Fig 1. SARS CoV PCR and serology results.
https://doi.org/10.1371/journal.pone.0253625.g001
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The mortality was 33% (6/18) in MIS-C non KD cohort. Majority 5/6 (83%) belonged to
MIS-C VM group and one patient had suspicion of TSS. All survivors were prescribed oral
prednisolone on discharge along with low dose Aspirin. Seventy five percent (9) of these fol-
lowed their primary cardiologist and reported to have resolution of symptoms, laboratory
markers and echocardiographic features within one month of onset of symptoms.
Comparison of historic KD and VM with MIS-C KD and VM
During the last 5 years; 30 patients were diagnosed with KD at the AKUH (0.48 cases per
month). From March till July 2020; 12 patients were diagnosed with MIS-C KD (2.4 cases per
month) which constitutes a 5-fold rise in cases (Fig 2). Comparison of two groups showed sig-
nificant difference in presentation (Table 3). There was no gender predominance,75% (9/12)
presented as atypical KD as compared to only 20% (6/30) in historic KD (p value =<0.013).
The median lymphocyte count (17 vs 34 x109/L, p =<0.091) and median platelet count (304
vs 573 x109/L, p =<0.013) were lower in MIS-C KD group when compared to the historic KD
group. The median C-Reactive Protein was higher in the MIS-C KD cohort (68vs 11 mg/L;
p = 0.040) as well (Fig 3). In the MIS-C group, 58.3% had coronary involvement, though
mainly (57%) perivascular brightness and majority (86%) resolved. In the historic KD cohort,
main coronary involvement was coronary dilation (50%) followed by aneurysm (33%) and
perivascular brightness (17%), with 56% resolution rate. The median left ventricular ejection
Fraction (LVEF) in MIS-C KD was57%(IQR = 46–61) vs 67% (IQR = 63–72) in historic KD (p
value =<0.001).
The previous five-year data of historic VM showed a total of 47 patients. The frequency was
0.78 cases per month as compared to 1.66 cases per month during the pandemic period, which
constitutes a 2.1-fold increase., Pericardial effusion was more likely to be seen in MIS-C VM
(78% vs 0% p value =<0.001) and reversal of LVEF to normal was more likely in MIS-C VM
survivors (100%vs 21.4% p value = 0.04). Whereas 51% of historic VM cohort still developed
dilated cardiomyopathy (DCMP), none of MIS-C VM developed DCMP (p value = 0.00
(Table 4).
Discussion
SARS-CoV-2 infection in children and adolescents can cause MIS-C, which shares clinical
similarities with KD, TSS and VM. We describe 30 hospitalized children with MIS-C
Fig 2. Number of cases with Kawasaki Disease (KD) and Viral Myocarditis (VM) over past 5 years.
https://doi.org/10.1371/journal.pone.0253625.g002
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diagnosed in first five months after the pandemic hit the city of Karachi Pakistan, in March
2020. This constitutes one of the largest cohort of patients reported from a low-or-middle
income country (LMIC). Our cohort of patients is younger and had a higher mortality rate
compared to published reports, but the presenting symptoms and range of organ involvement
was like that reported by others [3–5, 16–20].
The diagnosis of MIS-C was made in most patients based on a positive PCR or serology for
SARS-CoV-2. In nine patients in our cohort with either a negative PCR or serology or no
COVID testing performed, we made the diagnosis of MIS-C after the exclusion of other condi-
tions like bacterial and viral infections and with suspicion of exposure. We also compared
demographics, clinical feature, biochemical parameters, SARS-CoV-2 PCR results, and out-
comes of patients fulfilling WHO definition with history of contact and those with no history
of contact and found no difference between the groups. However, serology results were signifi-
cantly more likely to be positive in the group with positive history of contact. This highlights
the fact that in LMIC with high rates of community transmission and increased number of
Table 3. Comparison of clinical and laboratory characteristics of historic and MIS-C Kawasaki disease.
Characteristics Historic KD MIS-C KD Total P-value
N = 30 N = 12 N = 42
Demographic Characteristics
Gender, n (%) 0.390
Male 17 (57%) 11 (92%) 28 (67%)
Female 13 (43%) 1 (8%) 14 (33%)
Clinical Findings
Diagnosis, n (%) 0.013
KDa 24 (80%) 3 (25%) 27 (64%)
Atypical KD 6 (21%) 9 (75%) 15 (36%)
Coronary Type, n (%) 18(60%) 7(58%) 25(59%) 1.000
Dilated 9 (50%) 2 (29%) 11 (46%)
Aneurysm 6(33%) 1 (14%) 7(28%)
Echo brightness 3 (17%) 4 (57%) 7 (28%)
Laboratory Findings
Leucocyte count, Median (IQRb) (×109/L) 18 (15–22) 11(9–14) 16 (9–21) 0.091
Neutrophils, Median (IQRc) (×109/L) 56 (47–67) 75 (68–81) 66 (52–73) 0.013
Lymphocyte, Median (IQR) (×109/L) 34 (23–40) 17 (12–22) 28 (18–36) 0.013
Platelets Count, Median (IQR) (×109/L) 573 (498–895) 304 (245–389) 529 (368–682) 0.013
LVEF, Median (IQR) (%) 67 (63–72) 57 (46–61) 65 (60–72) <0.001
CRP, Median (IQR) (mg/L) 11 (5–18) 68 (25–167) 13 (5–33) 0.039
Treatment / Dosage
IVIGc, n (%) 0.260
Yes 30 (100%) 10 (83%) 40 (95%)
No 0 (0%) 2 (17%) 2 (5%)
Coronary involvement Outcome\Follow-up, n (%) n = 18 n = 7 n = 25 1.000
Resolved 10 (56%) 6 (86%) 16 (64%)
Not resolved 3(13%) 1(14%) 4 (16%)
No Follow up 5 (29%) 0(0%). 5(25%)
aKD = Kawasaki disease
bIQR = Interquartile range
cIVIG = Intravenous immunoglobulin.
https://doi.org/10.1371/journal.pone.0253625.t003
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asymptomatic (or mildly symptomatic) patients coupled with limited laboratory resources and
access to testing, history of exposure may not always be able to be ascertained. In the face of
wide community spread, history of contact may have less significance. Similar concern was
conveyed in some correspondence from South Africa [11].
MIS-C-KD like illness phenotype
KD is an autoimmune disease, seen in children < 5 years of age and hallmark is coronary
artery dilation and aneurysm formation. During the SARS-CoV-2 pandemic, we report a
5-fold increase in MIS-C related KD-like illness compared to the prior five years (Fig 1). A
30-fold increase in KD-like illness was reported from Italy during the SARS CoV-2 pandemic,
when compared to previous 5 years [16]. Ouladali et al from France reported an increase in
KD during SARS-CoV-2 and previously with influenza A H1N1 pandemic in 2009, thus
Fig 3. Laboratory features comparison in MISC and historic KD.
https://doi.org/10.1371/journal.pone.0253625.g003
Table 4. Comparison of clinical and laboratory characteristics of historic and MIS-C viral myocarditis.
Characteristics Historic Myocarditis MISC-Myocarditis Total p-value
N = 46 N = 10 N = 56
Laboratory Findings
Leucocyte count, Median (×109/L) IQR 14 (12–20) 9 (7–11) 14 (11–19) 0.169
Neutrophils Median (×109/L) IQR 49 (36–62) 73 (64–75) 51 (38–72) 0.040
Lymphocytes Median (×109/L) IQRβ 44 (30–56) 20 (15–30) 39 (20–53) 0.040
Platelets Median (×109/L) IQR 400 (300–515) 225 (129–335) 382 (249–478) 0.040
Pericardial Effusion <0.001
Present 0 (0%) 7 (78%) 7 (13%)
Not Present 46 (100%) 2 (22%) 48 (87%)
Outcome
Survived 33 (71%) 5 (50%) 38 (67%) 0.130
Normal Left ventricle Function 10 (30%) 5 (100%) 15 (39%) 0.040
Dilated Cardiomyopathy 23 (69%) 0 (0%) 23 (60%) <0.001
αMISC = Multisystem inflammatory Syndrome in children
βIQR = Interquartile range.
https://doi.org/10.1371/journal.pone.0253625.t004
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suggesting a role of viral infections as triggers for KD (21). We showed that MIS-C KD can be
considered a distinct entity, different from Historic KD. MIS-C KD differs from prior KD in
its presenting features (male predominance and higher percentage of atypical KD), laboratory
markers (lower lymphocyte and platelet counts and higher CRP), coronary artery involvement
pattern and outcome (more likely to have perivascular brightness followed by complete resolu-
tion within 1 month). These features may help in differentiating MIS-C KD from KD in an
LMIC and identify patients in which other laboratory investigations should be offered, as also
shown in previously published data [10, 16]. Our cohort of MIS-C KD had a mild course and
showed good response to IVIG, with complete resolution of laboratory and echocardiographic
abnormalities at 6 weeks of follow up. These results are like the ones reported from India but
different from France, where the course was more severe [10, 20, 21].
MIS-C VM and TSS phenotype
MIS-C VM has now been well described in the literature. MIS-C VM may be due to direct
myocardial damage or delayed host response as in KD. Clinical presentation can be varied,
ranging from mild symptoms to fulminant myocarditis [22, 23]. Our cohort showed fulminant
myocarditis, with 50%mortality, and complete recovery in survivors. Children with MIS-C
VM were treated primarily with steroids as limited supply and additional cost precluded treat-
ment with IVIG. Also, none of the children received Tocilizumab and Anakinra or Extracor-
poreal support with plasma exchange, or ventricular assist device, which are available and
frequently used in high income countries. The increased mortality in our patients with
depressed LVEF when compared to other phenotypes from the same cohort and other pub-
lished cases, could be multifactorial, including but not limited to delays in accessing care,
delayed referrals to facilities with pediatric cardiology and critical care services, and limited
availability of IVIG and other advance treatment options. Furthermore, if advanced treatments
were to become available in resource-limited environments, they would most benefit children
with MISC-VM.
We also compared MIS-C VM to Historic VM from previous five years and found remark-
able difference in presentation and outcome of MIS-C VM. The presentation was more likely
to be fulminant in children with MIS-C VM with decreased LVEF, severe valvar regurgitation
and presence of pericardial effusion. Similar findings have been reported by Grimaud et al.
[24] Though the mortality was high (50%), 100% of the survivors had recovered their LV func-
tion, valve regurgitation and pericardial effusion to normal within one month. In comparison,
the historic VM cohort showed 71% survivors, with progression of 70% survivors to DCMP
with persistent LV dysfunction, and complete recovery in remaining 30%. Our comparison
emphasizes that MIS-C VM behaves more like fulminant VM with increased mortality but
complete recovery, if treated promptly. Based on these results, we suggest early, aggressive
management of children with MIS-C VM, as reported by others as well [18, 25]. The mortali-
ties in our MIS-C VM cohort were within first 6 hours of presentation. The clinical presenta-
tion, along with distinct laboratory and echocardiographic features can help make the
diagnosis of MIS-C VM and timely management could limit mortality in this group [26].
Eight (26%) of our patients presented with symptoms consistent with TSS in the setting of
MIS-C. Their differentiating features from other subtypes were presence of vomiting, diarrhea,
fluid refractory shock, requiring inotropic support and muco-cutaneous changes and pre-
served cardiac functions. This sub type was different from myocarditis both in presentation
and outcome. More frequent coronary involvement (3 vs 0) and mild LV dysfunction with a
median EF of 48% vs 30% was seen in MIS-C TSS when compared to MIS-C VM. All patients
in this group received steroids and inotropes, and 25% received both IVIG and steroids. There
PLOS ONE Multisystem inflammatory syndrome in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0253625 June 21, 2021 10 / 13
was one mortality in this group, which was after 48 hours of admission. Due to a gap in our
coding system, we could not compare the MIS-C TSS group to a historic cohort of similar
patients like in other subgroups.
It is possible that the three phenotypes of MIS-C that we describe (KD, VM and TSS) repre-
sent various stages in the continuum of the evolving pathophysiology of MIS-C. It is hard to
ascertain the onset of infection with SARS-CoV-2 in most of our patients and the natural his-
tory of MIS-C is still to be fully understood.
We have been able to follow up 21 of the 24 (87.5%) patients who survived to discharge. All
survivors in our cohort received steroids while only 2/6 (40%) of the expired received steroids.
Results from the RECOVERY trail in adult patients hospitalized with COVID-19 requiring
respiratory support who received dexamethasone administration for 10 days showed a reduc-
tion in 28-day mortality [27]. Extrapolating this to MIS-C, we can say that steroids likely help
to modulate the hyper inflammatory and prothrombotic responses seen in severe COVID-19
disease. Further investigation into the role of steroids in MIS-C need to be performed.
These results are encouraging and suggest that early diagnosis and treatment can be lifesav-
ing. However, long-term follow up is required to perform surveillance for any late sequalae of
this illness.
Limitation of study
Our study is a report from two tertiary-care centers and does not constitute a city-wide or a
country-wide report. While aggregate data for COVID-19 cases does exist, no national or local
surveillance system to detect MIS-C currently exists in Pakistan [12]. Thus, no inference can
be made on rates of illness. Four patients (13%) patients could not get either PCR or serology
and the diagnosis of MIS-C was based on known contact with COVID-19 patients and their
laboratory features, 3 of these could not survive. Furthermore, we did not collect information
on diastolic dysfunction and strain assessment in echocardiographic assessment of the
patients. Given the quite high mortality and, the centers being referral centers, patients may
have been late in presentation or getting to the institutions. Another limitation was that classi-
fication of MI-C phenotypes has not been validated due to small sample size, in future data
registries for MISC may help validating this classification.
Conclusion
We report a large cohort of cases with MIS-C from Pakistan. Our data suggest that mortality
from VM-like MIS-C, probably can be more in LMIC compared to high income countries.
Our work demonstrates that COVID-19 and MIS-C are not benign conditions in children.
This is especially true when cost limits treatment. We have shown three distinct yet overlap-
ping phenotypes of MIS-C (KD, VM and TSS like presentations). In comparison to historic
cohorts, MIS-C KD and VM can be labeled as distinct entities based on their clinical, labora-
tory and echocardiographic features.
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